Antioxidant therapy in mechanical jaundice secondary to choledocholithiasis | Ukrainian Medical Journal

Maksymenko M.V.,Havryliuk R.O.

Main
Publications
Antioxidant therapy in mechanical jaundice secondary to choledocholithiasis

Antioxidant therapy in mechanical jaundice secondary to choledocholithiasis

February 25, 2025

Surgery

Maksymenko M.V.

Havryliuk R.O.

УДК: 616.36:577.1

DOI: 10.32471/umj.1680-3051.263260

Keywords :

Specialities :

Resume

Objective: to evaluate the efficacy of antioxidant therapy in improving liver function and clinical outcomes in patients with mechanical jaundice secondary to choledocholithiasis.

Materials and methods. We conducted a prospective randomized cohort study to assess the impact of antioxidant therapy on liver function recovery and overall condition improvement in patients with mechanical jaundice caused by choledocholithiasis. The participants were randomly assigned to one of the two groups: a control group that received standard conservative treatment and an antioxidant therapy group, which received additional treatment with vitamin C (1000 mg/day intravenously), vitamin E (400 IU/day orally), N-acetylcysteine (1200 mg/day orally), and glutathione (1200 mg/day intravenously).

Results. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels demonstrated a significantly faster decline in the antioxidant group compared to the control group (p<0.05). By day 7, ALT and AST levels in the antioxidant group had decreased to 40±5 and 35±6 U/L, respectively, versus 85±10 and 80±12 U/L in the control group. However, reductions in bilirubin (total and conjugated), alkaline phosphatase, and γ-glutamyl transferase levels were comparable between the two groups, with no statistically significant differences observed (p>0.05).

Conclusion. The results of this study provide a compelling rationale for incorporating antioxidant therapy into the treatment protocol for mechanical jaundice. Further large-scale, randomized controlled trials are warranted to confirm these findings and establish optimal dosing strategies.

References

1. Fevery J. (2008) Bilirubin in clinical practice: a review. Liver Int., 28(5): 592–605. doi.org/10.1111/j.1478-3231.2008.01716.x.
2. Liu D., Yu Q., Li Z. et al. (2021) UGT1A1 dysfunction increases liver burden and aggravates hepatocyte damage caused by long-term bilirubin metabolism disorder. Bioch. Pharmacol., 190: 114592. doi: 10.1016/j.bcp.2021.114592.
3. Perrone S., Lembo Ch., Giordano M. et al. (2023) Molecular mechanisms of oxidative stress-related neonatal jaundice. J. Bioch. Mol. Toxicol., 37(6): e23349.
4. Kumar A., Pant P., Basu S. et al. (2007) Oxidative stress in neonatal hyperbilirubinemia. J. Trop. Pediatr., 53(1): 69–71. doi: 10.1093/tropej/fml060.
5. Tell G., Gustincich S. (2009) Redox state, oxidative stress, and molecular mechanisms of protective and toxic effects of bilirubin on cells. Curr. Pharm. Des., 15: 2908–2914.
6. Ioniuc I., Lupu A., Tarnita I. et al. (2024) Insights into the Management of Chronic Hepatitis in Children-From Oxidative Stress to Antioxidant Therapy. Int. J. Mol. Sci., 25(7): 3908. doi: 10.3390/ijms25073908.
7. Lengyel G., Zsolt T. (2006) Antioxidáns kezelés krónikus májbetegségekben. Orvosi hetilap., 147(24): 1113–1118.
8. Moreno-Otero R., Trapero-Marugán M. (2010) Hepatoprotective effects of antioxidants in chronic hepatitis C. World J. Gastroenterol., 16(15): 1937–1938.
9. Jesús M., Moreno-Otero R. (2005) Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs, 65(17): 2445–2461.